Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

Manuscripts (4 of 4)

Years :

Search manuscripts :


Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning
Helen A. Dakin, Andrew Farmer, Alastair M. Gray, Rury R. Holman
Value in Health 2020;23:1340-1348. Published:Oct-2020. Epub:18-Aug-2020. PMID:33032778. doi:10.1016/j.jval.2020.05.018


The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
Andrew J. Farmer, Jason Oke, Wendy Hardeman, Lynne Tucker, Stephen Sutton, Ann-Louise Kinmonth, Simon Griffin, Rury R. Holman
Diabetes Res Clin Pract. 2016;120:56-64. Published:Oct-2016. Epub:30-Jul-2016. PMID:27522034. doi:10.1016/j.diabres.2016.07.004


Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial
H.A.W. Neil, U. Ceglarek, J. Thiery, S. Paul, A. Farmer, R. R Holman
Atherosclerosis 2010;213:512-517. Published:Dec-2010. Epub:18-Sep-2010. PMID:21036355. doi:10.1016/j.atherosclerosis.2010.09.013


Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA on behalf of the AFORRD study group
Diabetologia 2009;52:50-59. Published:Jan-2009. Epub:11-Nov-2008. PMID:19002433. doi:10.1007/s00125-008-1179-5